Novartis updates investors on company progress, says it expects to increase core margin in 2015

18 June 2015
novartis-basel-big

Swiss drug major Novartis (NOVN: VX) highlighted its strong innovation momentum and said it expects to increase core margin in 2015 due to portfolio transformation.

At its second Meet Novartis Management investor day, the company gathered more than 20 of its executives from pharmaceuticals, Alcon, Sandoz and Novartis Institutes for Biomedical Research to meet with investors and analysts.

Pharma

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical